Effects of bisoprolol on cardiac function and exercise in patients with heart failure;Efeito do bisoprolol sobre a função cardíaca e o exercício em pacientes com insuficiência cardíaca

Arquivos Brasileiros de Cardiologia

Volumn 88, Issue 3, 2007, Pages

  Issa, Victor Sarli ^a,b   Guimarães, Guilherme Vieira ^a   Rezende, Marcos Valério Coimbra ^a   Cruz, Fátima Das Dores ^a   Ferreira, Silvia Moreira Ayub ^a   Bacal, Fernando ^a   Bocchi, Edimar Alcides ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Adrenergic beta antagonists; Bisoprolol; Cardiac output, low; Exercise

Indexed keywords

ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARBON DIOXIDE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; OXYGEN;

ADULT; ARTICLE; CHAGAS DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EXERCISE; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEART VENTRICLE FUNCTION; HEMODYNAMICS; HUMAN; HYPOTENSION; MALE; OXYGEN CONSUMPTION; QUALITY OF LIFE; SPIROMETRY; ERGOMETRY; FOLLOW UP; HEART STROKE VOLUME; MIDDLE AGED; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PEAK EXPIRATORY FLOW; PROSPECTIVE STUDY; TIME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; BISOPROLOL; ERGOMETRY; EXERCISE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART RATE; HUMANS; MALE; MAXIMAL EXPIRATORY FLOW RATE; MIDDLE AGED; OXYGEN CONSUMPTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; SPIROMETRY; STATISTICS, NONPARAMETRIC; STROKE VOLUME; TIME FACTORS;

EID: 34249793704     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Sackner-Bernstein JD, Mancini DM. Rationale for treatment of patients with chronic heart failure with beta-blockade. J Am Coll Cardiol. 1995; 274: 1462-7.
2. Elser M, Kaye D, Lambert G, Jennings G. Adrenergic nervous system in heart failure. Am J Cardiol. 1997; 80 (11A): 7L-14L.
3. Fringerio M, Roubina E. Drugs for left ventricular remodeling in heart failure. Am J Cardiol. 2005; 96: 10L-18L.
4. Domanski MJ, Krause-Steinrauf H, Massie BM, Deedwania P, Follmann D, Kovar D, et al., BEST Investigators. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003; 9 (5): 354-63.
5. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Circulation. 2005; 112: e154-e235.
6. Witte KKA, Thackray S, Nikitin NP, Cleland JGF, Clark AL. The effects of long-term beta-blockade on the ventilatory responses to exercise in chronic heart failure. Eur J Heart Fail. 2005; 7: 612-7.
7. Bolger AP, Al-Nasser F. Beta-blockers for chronic heart failure: surviving longer but feeling better? Int J Cardiol. 2003; 92: 1-8.
8. de Groote P, Delour P, Lamblin N, Dagorn J, Verkindere C, Tison E, et al. Effects of bisoprolol in patients with stable congestive heart failure. Ann Cardiol Angeiol (Paris). 2004; 53 (4): 167-70.
9. Dubach P, Myers J, Bonetti P, Schertler T, Froelicher V, Wagner D, et al. Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging. Am Heart J. 2002; 143: 676-83.
10. Fowler MB. Effects of beta-blockers on symptoms and functional capacity in heart failure. Am J Cardiol. 1997; 80 (11A): 55L-58L.
11. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003; 362 (9377): 7-13.
12. Taylor AL, Wright JT Jr. Should ethnicity serve as the basis for clinical trial design? Importance of race/ethnicity in clinical trials: lessons from the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Circulation. 2005; 112 (23): 3654-60.
13. Bocchi EA, Bacal F, Bellotti G, Carrara D, Ramires JA. Effects of Carvedilol (beta 1, beta 2, alpha 1 blocker) on refractory congestive heart failure. Arq Bras Cardiol. 1998, 71 (2): 169-73.
14. Chizzola PR, Freitas HF, Caldas MA, da Costa JM, Meneghetti C, Marinho NV, et al. Effects of carvedilol in heart failure due to dilated cardiomyopathy. Results of a double-blind randomized placebo-controlled study (CARIBE study). Arq Bras Cardiol. 2000; 74 (3): 233-42.
15. Chizzola PR, Gonçalves de Freitas HF, Marinho NV, Mansur JA, Meneghetti JC, Bocchi EA. The effect of beta-adrenergic receptor antagonism in cardiac sympathetic neuronal remodeling in patients with heart failure. Int J Cardiol. 2006; 106 (1): 29-34.
16. Maia ER, Villacorta H, Subietta CG, Munhoz C, Romeo Filho LJ, Mesquita ET. Use of propranolol in heart failure patients: safety, tolerability and effects in left ventricular function. Rev Port Cardiol. 2001; 20 (4): 383-99.
17. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971; 285: 1441-6.
18. Richardson P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation. 1996; 93: 841-2.
19. The Criteria Committee of the New York Heart Association Nomenclature and Criteria for Diagnosis. 9th ed. Boston: Little, Brown; 1994.
20. Henry WI, Gardin JM, Ware JH. Echocardiographic measurements in normal subjects from infancy to old age. Circulation. 1980; 62: 1054-61.
21. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994; 90: 1765-73.
22. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353 (9146): 9-13.
23. Massie BM, Kramer B, Haughom F. Acute and long-term effects of vasodilator therapy on resting and exercise hemodynamics and exercise tolerance. Circulation. 1981; 64: 1218-26.
24. Maskin CS, Kugler J, Sonnenblick EH, LeJemtel TH. Acute inotropic stimulation with dopamine in severe congestive heart failure: beneficial hemodynamic effect at rest but not during maximal exercise. Am J Cardiol. 1983; 52: 1028-32.
25. Savin WM, Haskell WL, Schroeder JS, Stinson EB. Cardiorespiratory responses of cardiac transplant patients to graded, symptom-limited exercise. Circulation. 1980; 62 (1): 55-60.